Tesamorelin and Cognitive Function: Research Insights from Neuroendocrinology

In a research highlight published by McLarnon (2012) in Nature Reviews Endocrinology, the peptide tesamorelin, a synthetic analogue of growth hormone–releasing hormone (GHRH), was discussed in the context of its potential effects on cognitive functioning in older adults. This summary drew on a randomized clinical research study in which tesamorelin was administered daily to a group of older participants, including both healthy individuals and those with mild cognitive impairment, with the aim of investigating endocrine and neurocognitive outcomes.

According to the findings referenced in the review highlight by McLarnon (2012), participants in the underlying clinical study self-administered 1 mg of tesamorelin each evening for 20 weeks. The researchers measured a range of outcomes, including serum levels of insulin-like growth factor-1 (IGF-1), performance on cognitive tests assessing executive function and memory, mood, sleep quality, and metabolic indicators such as glucose tolerance. Tesamorelin was noted to significantly increase IGF-1 levels to concentrations typically observed in much younger adults, and these elevated levels were sustained throughout the day following treatment.

In the cognitive assessments reported within the study highlighted by McLarnon (2012), tesamorelin was associated with improvements in certain measures of cognitive function. Specifically, performance on tests of executive functioning and, to a lesser degree, short-term verbal memory improved over the course of treatment in both healthy older adults and those with mild cognitive impairment. The researchers interpreted these findings to suggest that interventions involving GHRH analogues such as tesamorelin might support aspects of cognitive performance that decline with age or in early neurodegenerative processes.

While the Nature Reviews Endocrinology article itself was a brief highlight rather than a full research paper, it summarized clinically relevant results from the underlying trial. That study’s findings contributed to ongoing scientific interest in growth hormone axis modulation and its effects beyond traditional metabolic endpoints, extending into domains such as neural function and age-related cognitive change. Additional research would be necessary to define mechanisms, the role of sustained IGF-1 increases, and the applicability of these findings across broader populations.

Important Notice

This content is provided for educational and informational purposes only. The research discussed relates exclusively to clinical and scientific investigation. No claims are made regarding biological activity, therapeutic use, or clinical outcomes beyond those reported in the referenced research. Peptides and compounds referenced are not intended for human use outside of controlled research contexts.

Sources

McLarnon A. (2012). Tesamorelin can improve cognitive function. Nature Reviews Endocrinology. doi: 10.1038/nrendo.2012.151.